Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Ensysce Biosciences Inc ENSCW


Primary Symbol: ENSC

Healthcare Biotechnology
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ENSC)

Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

Accesswire 9 hours ago

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Accesswire 6 days ago

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Accesswire April 9, 2024

MRC Global Announces Agreement with Engine Capital and Appointment of Daniel Silvers to the Board of Directors

GlobeNewswire April 2, 2024

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Accesswire March 15, 2024

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Accesswire February 27, 2024

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

Accesswire February 21, 2024

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Accesswire February 15, 2024

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Accesswire February 13, 2024
View More News ››

Opinion & Analysis (NDAQ:ENSC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ENSC)

Ensysce Biosciences Selected to Present at American Associat

JUST IN: $ENSC Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference~ PF614-MPAR recognized...
whytestocks - February 6, 2024

(NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting

Breaking News: $ENSC (NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting2024-01-31 09:03:48 ET DENVER, Colo., Jan. 31, 2023...
whytestocks - January 31, 2024

Ensysce Biosciences Announces FDA Breakthrough Therapy Desig

Just In: $ENSC Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR~ FDA acknowledges significant...
whytestocks - January 23, 2024

ENSC.... I have to give kudos to ENSC

I found this Co played by the rules and they were transparent enough to be able to pick spots to enter and exit. Most Co's are the...
Iseneschal - May 10, 2023

ENSC....filed yesterday...Check it out!

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001716947/000149315223015752
Iseneschal - May 9, 2023

ENSC..... Great way to start off the morning ; )

That's a big F'king Cha Ching Sold all into the strength...... I feel confident this will go even higher ...past $7...
Iseneschal - May 9, 2023
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »